Skip to main content
Clinical Trials/NCT03910374
NCT03910374CompletedNot Applicable

Role of Leukocyte- and Platelet-Rich Fibrin Membranes in Endoscopic Endonasal Skull Base Reconstruction

Universitaire Ziekenhuizen KU Leuven6 sites in 2 countries220 target enrollmentStarted: November 1, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
220
Locations
6
Primary Endpoint
Cost-effectiveness evaluation based on the effectiveness and the costs of L-PRF versus the current golden standard (Tachosil and Tisseel).

Study Overview

Brief Summary

Prospective investigation of the effectivity of L-PRF membranes for skull base reconstruction after endoscopic endonasal skull base surgery (transsphenoidal) versus classical closure techniques.

Detailed Description

The investigators want to demonstrate in a prospective, randomized trial including 220 patients undergoing endoscopic endonasal skull base surgery that the use of L-PRF is non-inferior to classical fibrin sealants.

Approximately 220 patients undergoing cranial surgery will be enrolled in this randomized, controlled, single-blinded multicenter study to evaluate the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Single (Participant)

Masking Description

Participants stay masked during the trial, care provider and investigators are unblinded at the surgical procedure and from thereon

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with lesions of the sellar/parasellar region
  • Age > 18 and < 70 years
  • Written informed consent
  • Willingness to adhere to visit schedules

Exclusion Criteria

  • Age < 18 and > 70 years
  • Any underlying rhinological condition like nasal polyps, which may interfere with the obtained results
  • Any disorder which might compromise the ability of a patient to give truly informed consent for participation in this study
  • Enrollment in other investigational drug trial(s)

Arms & Interventions

L-PRF

Active Comparator

In this arm, dural closure will be performed with the autologous L-PRF

Intervention: Dural closure (Procedure)

Classical Treatment

Placebo Comparator

In this arm, dural closure will be performed with the classical fibrine sealants.

Intervention: Dural closure (Procedure)

Outcomes

Primary Outcomes

Cost-effectiveness evaluation based on the effectiveness and the costs of L-PRF versus the current golden standard (Tachosil and Tisseel).

Time Frame: 4 years

Cost-effectiveness evaluation: compare the costs and the effectiveness of L-PRF versus commercial fibrin sealants.

To compare the prevalence of CSF-leaks after L-PRF closure and after the classical closure techniques for sellar defects to demonstrate non-inferiority

Time Frame: 4 years

The primary aim of this study is identifying the role of L-PRF in the endoscopic endonasal closure of skull base defects. More specific, we want to demonstrate in a prospective, randomized trial that the use of L-PRF is non-inferior to classical closure techniques regarding prevalence of CSF-leaks The number of patients with a CSF-leak will be compared between both treatment groups.

Secondary Outcomes

  • To identify potential risk for closure-failures based on the size of the lesion(4 years)
  • To evaluate if the pathology is a potential risk factor for closure-failures(4 years)
  • Evaluate the potential interference of the L-PRF membranes with post-operative imaging by comparing the tumor residue evaluation 3 months and 1 year after surgery(4 years)
  • To evaluate if the age of the patient is a potential risk factor for closure-failures(4 years)
  • Evaluate the effect of L-PRF versus the current golden standard (Tachosil and Tisseel) on post-operative symptoms based on a visual analogue scale(4 years)
  • Evaluate the effect of L-PRF versus the current golden standard (Tachosil and Tisseel) on post-operative symptoms based on the SNOT-22(4 years)
  • Evaluate the effect of L-PRF versus the current golden standard (Tachosil and Tisseel) on post-operative symptoms based on the skull base questionnaire(4 years)
  • Evaluate the effect of L-PRF versus the current golden standard (Tachosil and Tisseel) on post-operative symptoms based on the EQ-5D(4 years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Laura Van Gerven

Clinical professor, Doctor

Universitaire Ziekenhuizen KU Leuven

Study Sites (6)

Loading locations...

Similar Trials